CH Biotech R&D Co (TPE:6534) ROCE %: 8.81% (As of Dec. 2025)


TPE:6534 CH Biotech R&D Co Ltd TPE:6534
84 GF Score
Price NT$90.10
GF Value NT$100.55
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is CH Biotech R&D Co ROCE %?

CH Biotech R&D Co TPE:6534 +0.33% 84 ROCE % is 8.81% as of Dec. 2025. GuruFocus rates TPE:6534 with a GF Score™ of 84/100 and a GF Value™ of NT$100.55 (Modestly Undervalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CH Biotech R&D Co's annualized ROCE % for the quarter that ended in Dec. 2025 was 8.81%.

CH Biotech R&D Co  (TPE:6534) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CH Biotech R&D Co ROCE % Related Terms

CH Biotech R&D Co ROCE % Historical Data

* Premium members only.

The historical data trend for CH Biotech R&D Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CH Biotech R&D Co ROCE % Chart

CH Biotech R&D Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.16 22.29 21.68 21.15 20.08

CH Biotech R&D Co Quarterly Data
Jun20 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 67.63 5.04 -2.32 8.81
TPE:6534
84GF Score
CH Biotech R&D Co Ltd TPE:6534
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CH Biotech R&D Co ROCE % Calculation

CH Biotech R&D Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=585.838/( ( (3629.183 - 646.93) + (3574.474 - 721.513) )/ 2 )
=585.838/( (2982.253+2852.961)/ 2 )
=585.838/2917.607
=20.08 %

CH Biotech R&D Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=250.796/( ( (3682.06 - 839.63) + (3574.474 - 721.513) )/ 2 )
=250.796/( ( 2842.43 + 2852.961 )/ 2 )
=250.796/2847.6955
=8.81 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 8.81% mean?
CH Biotech R&D Co (TPE:6534) has a ROCE % of 8.81% as of Dec. 2025.
Is CH Biotech R&D Co's ROCE % too high?
CH Biotech R&D Co's current ROCE % is 8.81%. The Agriculture industry median ROCE % is 9.49. CH Biotech R&D Co's value of 8.81% is 7.2% below this industry median. Overall, CH Biotech R&D Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CH Biotech R&D Co's ROCE % compare to CTVA and CF?
CH Biotech R&D Co's ROCE % of 8.81% can be compared against companies in the Agriculture industry. The industry median ROCE % is 9.49. CH Biotech R&D Co's value of 8.81% is 7.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for an Agriculture company?
The median ROCE % among Agriculture companies is 9.49, based on 252 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CH Biotech R&D Co's current ROCE % of 8.81% is 7.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Agriculture industry, the median ROCE % is 9.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CH Biotech R&D Co's current ROCE % is 8.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CH Biotech R&D Co stock overvalued right now?
Based on GuruFocus' analysis, CH Biotech R&D Co (TPE:6534) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$100.55, compared to a current price of NT$90.10 — trading 10.4% below its estimated fair value. The current ROCE % is 8.81% and 7.2% below the Agriculture industry median of 9.49. CH Biotech R&D Co's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For CH Biotech R&D Co (TPE:6534), the current ROCE % is 8.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CH Biotech R&D Co (TPE:6534) Overvalued in 2026?

Based on GuruFocus' analysis, CH Biotech R&D Co stock appears to be undervalued. The current stock price of NT$90.10 is trading 10.4% below its estimated GF Value™ of NT$100.55. GuruFocus considers CH Biotech R&D Co to be Modestly Undervalued.

Key valuation signals for TPE:6534:

  • ROCE %: 8.81%
  • GF Value™: NT$100.55 vs. price of NT$90.10 (10.4% below fair value)
  • GF Score™: 84/100 with 1 warning sign
  • Industry Position: 7.2% below the Agriculture median

No single metric tells the full story. See the TPE:6534 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CH Biotech R&D Co Business Description

Address No. 89, Wenxian Road, Nantou County, Nantou City, TWN, 540001
CH Biotech R&D Co Ltd is a Taiwan-based company engaged in the manufacture and sales of fertilizer, as well as providing biotechnology services. It is engaged in the research, development, manufacturing, and sales of proprietary plant growth regulators and specialty micronutrient fertilizers. It offers NutriSync 3D plant growers in the form of boron and molybdenum, NutriSync D liquid formulation for dicot crops, CHB-HS for reducing carbon emissions in crop production, CHB-BB2, fruit quality enhancers, and other related products. The company has one reportable segment, Agricultural Biotechnology. Geographically, it derives maximum revenue from the United States, and the rest from other countries.
84GF Score

Get the complete analysis for TPE:6534

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$90.10
Price
NT$100.55
GF Value